Use of CD23 Antagonists for the Treatment of Neoplastic Disorders
Methods and kits for the treatment of neoplastic disorders comprising the use of a CD23 antagonist are provided. The CD23 antagonist may be used alone or in combination with chemotherapeutic agents. In particularly preferred embodiments the CD23 antagonists may be used to treat B cell chronic lymphocytic leukemia (B-CLL).
1 . A method of treating a neoplastic disorder in a mammal in need thereof comprising administering a therapeutically effective amount of a CD23 antagonist to said mammal.
2 . The method of claim 1 wherein said CD23 antagonist is selected from the group consisting of CD23 reactive polypeptides, CD23 reactive peptides, CD23 reactive small molecules, and combinations thereof.
3 . The method of claim 2 wherein said CD23 reactive polypeptide comprises a monoclonal antibody or a polyclonal antibody.
4 . The method of claim 3 wherein said CD23 reactive polypeptide comprises a monoclonal antibody.
5 . The method of claim 4 wherein said monoclonal antibody is selected from the group consisting of chimeric antibodies and humanized antibodies.
6 . The method of claim 5 wherein said monoclonal antibody is a chimeric antibody and said chimeric antibody is primatized.
7 . The method of claim 6 wherein said primatized antibody is IDEC-152.
8 . The method of claim 7 wherein said neoplastic disorder is selected from the group consisting of relapsed Hodgkin's disease, resistant Hodgkin's disease high grade, low grade and intermediate grade non-Hodgkin's lymphomas, B cell chronic lymphocyte leukemia (B-CLL), lymhoplasmacytoid lymphoma (LPL), mantle cell lymphoma (MCL), follicular lymphoma (FL), diffuse large cell lymphoma (DLCL), Burkitt's lymphoma (BL), AIDS-related lymphoma, monocytic B cell lymphoma, angioimmunoblastic lymphoadenopathy, small lymphocytic; follicular, diffuse large cell; diffuse small cleaved cell; large cell immunoblastic lymphoblastoma; small, non-cleaved; Burkitt's and non-Burkitt's; follicular, predominantly large cell; follicular, predominantly small cleaved cell; and follicular, mixed small cleaved and large cell lymphomas.
9 . The method of claim 8 wherein said neoplastic disorder it B cell chronic lymphocytic leukemia (B-CLL).
10 . The method of claim 1 wherein said neoplastic disorder is selected from the group consisting of relapsed Hodgkin's disease, resistant Hodgkin's disease high grade, low grade and intermediate grade non-Hodgkin's lymphomas, B cell chronic lymphocytic leukemia (B-CLL), lymhoplasmacytoid lymphoma (LPL), mantle cell lymphoma (MCL), follicular lymphoma (FL), diffuse large cell lymphoma (DLCL), Burkitt's lymphoma (BL), AIDS-related lymphomas, monocytic B cell lymphoma, angioimmunoblastic lymphoadenopathy, small lymphocytic; follicular, diffuse large cell; diffuse small cleaved cell; large cell immunoblastic lymphoblastoma; small, non-cleaved; Burkitt's and non-Burkitt's; follicular, predominantly large cell; follicular, predominantly small cleaved cell; and follicular, mixed small cleaved and large cell lymphomas.
11 . The method of claim 10 wherein said neoplastic disorder is B cell chronic lymphocytic leukemia (B-CLL).
12 . The method of claim 1 wherein said CD23 antagonist is associated with a cytotoxic agent.
13 . The method of claim 12 said cytotoxic agent is a radioisotope.
14 . The method of claim 1 further comprising the step of administering a chemotherapeutic agent.
15 . The method of claim 14 wherein said chemotherapeutic agent comprises an antibody.
16 . The method of claim 15 wherein said antibody reacts with or binds to CD 19, CD20, CD22, CD40, CD40L, CD52 or B7.
17 . The method of claim 14 wherein said chemotherapeutic agent comprises fludarabine.
18 . A method of treating a neoplastic disorder in a mammal comprising the steps of:
administering a therapeutically effective amount of at least one chemotherapeutic agent to said mammal; and
administering a therapeutically effective amount of at least one CD23 antagonist to said patient wherein said chemotherapeutic agent and said CD23 antagonist may be administered in any order or concurrently.
19 . The method of claim 18 wherein said CD23 antagonist is selected from the group consisting of CD23 reactive polypeptides, CD23 reactive peptides, CD23 reactive small molecules, and combinations thereof.
20 . The method of claim 19 wherein said CD23 reactive polypeptide comprises a monoclonal antibody or a polyclonal antibody.
21 . The method of claim 20 wherein said CD23 reactive polypeptide comprises a monoclonal antibody.
22 . The method of claim 21 wherein said monoclonal antibody is selected from the group consisting of chimeric antibodies and humanized antibodies.
23 . The method of claim 22 wherein said monoclonal antibody is IDEC-152.
24 . The method of claim 18 wherein said chemotherapeutic agent comprises an antibody.
25 . The method of claim 24 wherein said antibody reacts with or binds to CD19, CD20, CD22, CD40, CD40L, CD52 or B7.
26 . The method of claim 18 wherein said neoplastic disorder is selected from the group consisting of relapsed Hodgkin's disease, resistant Hodgkin's disease high grade, low grade and intermediate grade non-Hodgkin's lymphomas, B cell chronic lymphocytic leukemia (B-CLL), lymhoplasmacytoid lymphoma (LPL), mantle cell lymphoma (MCL), follicular lymphoma (FL), diffuse large cell lymphoma (DLCL), Burkitt's lymphoma (BL), AIDS-related lymphomas, monocytic B cell lymphoma, angioimmunoblastic lymphoadenopathy, small lymphocytic; follicular, diffuse large cell; diffuse small cleaved cell; large cell immunoblastic lymphoblastoma; small, non-cleaved; Burkitt's and non-Burkitt's; follicular, predominantly large cell; follicular, predominantly small cleaved cell; and follicular, mixed small cleaved and large cell lymphomas.
27 . The method of claim 18 wherein said neoplastic disorder is B cell chronic lymphocytic leukemia (B-CLL).
28 - 40 . (canceled)
41 . A method of inducing apoptosis in malignant cells comprising contacting said malignant cells with an apoptosis inducing amount of a CD23 antagonist.
42 . The method of claim 41 wherein said CD20 antagonist is selected from the group consisting of CD23 reactive polypeptides, CD23 reactive peptides, CD23 reactive small molecules, and combinations thereof.
43 . The method of claim 41 wherein said CD23 reactive polypeptide comprises a monoclonal antibody or a polyclonal antibody.
44 . The method of claim 43 wherein said CD23 reactive polypeptide comprises a monoclonal antibody.
45 . The method of claim 44 wherein said monoclonal antibody is selected from the group consisting of chimeric antibodies and humanized antibodies.
46 . The method of claim 44 wherein said monoclonal antibody is IDEC-152.
47 . The method of claim 41 further comprising the step of contacting said malignant cells with a chemotherapeutic agent.
48 . The method of claim 47 wherein said chemotherapeutic agent comprises an antibody.
49 . The method of claim 48 wherein said antibody reacts with or binds to CD19, CD20, CD22, CD40, CD40L, CD52 or B7.
50 . The method of claim 41 wherein said malignant cells are contacted in vivo.
51 - 54 . (canceled)